ICOSAVAX
Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candida... tes targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.
ICOSAVAX
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2017-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.icosavax.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
161 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Pyxis Oncology
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Sanofi Ventures
Sanofi Ventures investment in Series B - Icosavax
Qiming Venture Partners USA
Qiming Venture Partners USA investment in Series B - Icosavax
RA Capital Management
RA Capital Management investment in Series B - Icosavax
Viking Global Investors
Viking Global Investors investment in Series B - Icosavax
Omega Funds
Omega Funds investment in Series B - Icosavax
Open Philanthropy Project
Open Philanthropy Project investment in Series B - Icosavax
Perceptive Advisors
Perceptive Advisors investment in Series B - Icosavax
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Icosavax
NanoDimension
NanoDimension investment in Series B - Icosavax
Surveyor Capital
Surveyor Capital investment in Series B - Icosavax
Official Site Inspections
http://www.icosavax.com Semrush global rank: 2.96 M Semrush visits lastest month: 5.5 K
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Icosavax"
Acquisition of Icosavax Completed - AstraZeneca
Feb 19, 2024 The acquisition was completed through a tender offer to purchase all outstanding shares of Icosavax for a price of $15.00 per share in cash up front, plus a non-tradable …See details»
AstraZeneca to acquire Icosavax, including potential first-in-class …
Dec 12, 2023 Icosavax VLP technology VLPs are a proven technology with multiple products on the market, including vaccines for human papillomavirus and hepatitis B. 6 While currently …See details»
About - Icosavax
Better vaccines may be possible with our VLP approach Working to empower a better immune response Icosavax was founded in 2017 with a mission to protect at-risk populations through …See details»
AstraZeneca completes acquisition of Icosavax – Company …
Feb 19, 2024 The acquisition was completed through a tender offer to purchase all outstanding shares of Icosavax for a price of $15.00 per share in cash up front, plus a non-tradable …See details»
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
Dec 12, 2023 - Icosavax stockholders to receive $15.00 per share in cash at closing plus non-tradeable contingent value right (CVR) of up to $5.00 per share - - Representing a total equity …See details»
Icosavax - Crunchbase Company Profile & Funding
Organization. Icosavax . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... (RSV), human metapneumovirus (hMPV), and severe acute respiratory …See details»
AstraZeneca to Acquire Icosavax in Deal Valued at ... - PharmTech
Jan 2, 2024 On Dec. 12, 2023, AstraZeneca announced a definitive agreement to acquire Icosavax, a US-based clinical stage biopharmaceutical company focused on developing …See details»
Acquisition of Icosavax Completed - AstraZeneca
Feb 19, 2024 The acquisition was completed through a tender offer to purchase all outstanding shares of Icosavax for a price of $15.00 per share in cash up front, plus a non-tradable …See details»
Icosavax Shares Take Flight on Takeover by AstraZeneca
Dec 12, 2023 Icosavax shares were recently up 49% to $15.59 in premarket trading. Write to Colin Kellaher at [email protected] (END) Dow Jones Newswires. December 12, 2023 …See details»
AstraZeneca to acquire Icosavax – Company Announcement
Dec 12, 2023 Adam Simpson, Chief Executive officer, Icosavax, said: "We are pleased to announce the proposed acquisition of Icosavax by AstraZeneca as we believe it offers the …See details»
AstraZeneca to buy Icosavax for $1.1B
Today we learned that Icosavax, a Seattle-based vaccine design company born from innovative research conducted here at the Institute for Protein Design, will be acquired by AstraZeneca in …See details»
AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 …
Dec 12 (Reuters) - AstraZeneca , opens new tab said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax , opens new tab in a deal valued at up to …See details»
AstraZeneca completes acquisition of Icosavax
Feb 19, 2024 The acquisition was completed through a tender offer to purchase all outstanding shares of Icosavax for a price of $15.00 per share in cash up front, plus a non-tradable …See details»
Why AstraZeneca Is Buying Icosavax For $1.1 Billion - Investopedia
Dec 12, 2023 Shares of Icosavax skyrocketed over 48% in early trading Tuesday after AstraZeneca agreed to purchase the biopharma company for $1.1 billion to expand its reach …See details»
AZ agrees $1.1bn deal to buy RSV jab developer Icosavax
6 days ago The $15-per-share deal is a 43% premium to Icosavax’s closing share price yesterday and values the company at around $1.1 billion, of which $800 million is payable …See details»
AstraZeneca to acquire vaccine maker Icosavax for up to $1.1B
Dec 12, 2023 Dive Brief: AstraZeneca on Tuesday reached a deal to acquire vaccine developer Icosavax in a deal worth up to $1.1 billion. Per deal terms, AstraZeneca will acquire Icosavax’s …See details»
Icosavax Announces Positive Topline Interim Phase 2 Results for ...
Dec 11, 2023 Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life …See details»
AstraZeneca to Acquire Icosavax, Including Potential First-in
Dec 12, 2023 AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, …See details»
Icosavax: Giving VLPs the VIP Treatment - genengnews.com
Apr 13, 2021 Icosavax emerged from stealth mode in 2019 with $51 million in Series A financing. The Series B was led by RA Capital Management. RA Capital’s founder and …See details»